WuXi PharmaTech Completes Expansion Of St. Paul, Minnesota, Testing Facility
05/12/2014
A new laboratory will offer expanded capacity for existing services, like particle identification and extractable/leachable testing, and add a new service—dynamic light scattering for nanoparticle characterization. These services are required by the FDA for filings of medical devices or biologics, the company said. The expansion is designed on a flexible floor plan that allows rapid scale-up of technologies to increase capacities for chemical analysis of medical materials. The new expanded laboratory will begin operation by the end of June.
"WuXi is committed to helping medical device and biologics companies bring their products to market faster," said Dr. Ge Li, Chairman/CEO of WuXi PharmaTech. "This facility and WuXi's trained staff will better serve our customers' growing need to quantify the chemical safety of materials used in medical devices and biologics."
Project Announcements
Australia-Based Aquatic Leisure Technologies Group Plans Opp, Alabama, Manufacturing Operations
12/11/2025
Teradyne Plans Wixom, Michigan, Robotics Operations
12/11/2025
Robinson Plans Altoona, Iowa, Manufacturing Operations
12/11/2025
BioTouch Expands Columbus, Georgia, Operations
12/11/2025
Natrion Plans Erie County, New York, Battery Components Operations
12/11/2025
Czech-Based GZ PrintPak Expands Mount Pleasant, Wisconsin, Manufacturing Operations
12/11/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
How Canada Stays Competitive
Q3 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025